PharmaCyte Biotech Valuation
| PMCB Stock | USD 0.71 0.06 7.79% |
PharmaCyte Biotech is fairly valued. PharmaCyte Biotech holds a recent Real Value of $0.68 per share. The prevailing price of the company is $0.71. Our model determines the value of PharmaCyte Biotech from analyzing the company fundamentals such as Shares Outstanding of 10.13 M, return on equity of -0.18, and Shares Owned By Institutions of 4.27 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting PharmaCyte Biotech's valuation include:
Fairly Valued
Today
Please note that PharmaCyte Biotech's price fluctuation is out of control at this time. Calculation of the real value of PharmaCyte Biotech is based on 3 months time horizon. Increasing PharmaCyte Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since PharmaCyte Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PharmaCyte Stock. However, PharmaCyte Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.71 | Real 0.68 | Hype 0.7 | Naive 0.44 |
The real value of PharmaCyte Stock, also known as its intrinsic value, is the underlying worth of PharmaCyte Biotech Company, which is reflected in its stock price. It is based on PharmaCyte Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of PharmaCyte Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of PharmaCyte Biotech helps investors to forecast how PharmaCyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PharmaCyte Biotech more accurately as focusing exclusively on PharmaCyte Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use PharmaCyte Biotech's intrinsic value based on its ongoing forecasts of PharmaCyte Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against PharmaCyte Biotech's closest peers. If more than one evaluation category is relevant for PharmaCyte Biotech we suggest using both methods to arrive at a better estimate.
PharmaCyte Biotech Cash |
|
PharmaCyte Biotech Total Value Analysis
PharmaCyte Biotech is at this time forecasted to have valuation of (7.51 M) with market capitalization of 7.2 M, debt of 3.28 M, and cash on hands of 82.23 M. The negative valuation of PharmaCyte Biotech may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the PharmaCyte Biotech fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(7.51 M) | 7.2 M | 3.28 M | 82.23 M |
PharmaCyte Biotech Asset Utilization
One of the ways to look at asset utilization of PharmaCyte is to check how much profit was generated for every dollar of assets it reports. PharmaCyte Biotech holds a negative application of assets of -0.0476 pct., losing $4.76E-4 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of PharmaCyte Biotech shows how discouraging it operates for each dollar spent on its assets.PharmaCyte Biotech Ownership Allocation
PharmaCyte Biotech holds 8.56 pct. of its outstanding shares held by insiders and 4.27 pct. owned by third-party entities.PharmaCyte Biotech Profitability Analysis
Net Income was 30.66 M with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates PharmaCyte Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in PharmaCyte Biotech and how it compares across the competition.
About PharmaCyte Biotech Valuation
The stock valuation mechanism determines PharmaCyte Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of PharmaCyte Biotech. We calculate exposure to PharmaCyte Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PharmaCyte Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (151.13) | (143.57) | |
| Operating Profit Margin | (124.64) | (130.87) | |
| Net Loss | (118.27) | (124.19) | |
| Gross Profit Margin | 0.24 | 0.23 |
PharmaCyte Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of PharmaCyte Biotech and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value PharmaCyte we look at many different elements of the entity such as PharmaCyte's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as PharmaCyte Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use PharmaCyte Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes PharmaCyte Biotech's worth.Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |